Profectus BioSciences to Present at Upcoming Investor and Industry Conferences

BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for chronic viral infections, announced today that the company will present at three upcoming conferences, as well as the online industry forum BioConference Live. These conferences will take Profectus BioSciences across the country and provide several unique opportunities for one-on-one meetings as the company continues to grow its business and its pipeline.

Shawn Patrick O’Brien, President and Chief Executive Officer of Profectus BioSciences, commented, “The Company has made significant progress in our vaccine programs in Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV), and we look forward to advancing our plans to enter the clinic in the coming months. We continue to seek out strategic partnering opportunities for our vaccines and NF-kB inhibitor programs.”

The 8^th Annual BIO Investor Forum, October 28-29, 2009, San Francisco, CA
Oral Presentation:

Who:	Shawn Patrick O’Brien
Title:	President and Chief Executive Officer
When:	Thursday, October 29, 11:30 AM
Where:	Presidio Room, The Palace Hotel
Website:	http://investorforum.bio.org/opencms/bif/2009/


2009 MAC Alliance Conference, November 3-4, 2009, Philadelphia, PA
Oral Presentation:

Who:	Shawn Patrick O’Brien
Title:	President and Chief Executive Officer
When:	Wednesday, November 4, 11:27 AM
Where:	The Philadelphia Convention Center
Website:	http://macalliance.basecampbusiness.com/node/4753


2009 Mid-Atlantic Bio, November 4-6, 2009, Washington, DC
Oral Presentation:

Who:	Shawn Patrick O’Brien
Title:	President and Chief Executive Officer
When:	Thursday, November 5, 11:45-11:55 AM
Where:	The Washington Convention Center
Website:	http://midatlanticbio.org/


Panel: “Vaccines: Biotech’s Next ‘Big Thing’”

Who:	Shawn Patrick O’Brien
Title:	President and Chief Executive Officer
When:	Friday, November 6, 11:15 AM – 12:30 PM
Where:	The Washington Convention Center
Website:	http://midatlanticbio.org/


BioConference Live, November 17-19, 2009
Webcast: http://www.bioconferencelive.com/register.php

Who:	Shawn Patrick O’Brien
Title:	President and Chief Executive Officer
When:	Tuesday, November 17, 10:00 AM
Website:	http://www.bioconferencelive.com/

About Profectus BioSciences Inc.

Profectus Biosciences is an innovative R&D clinical-stage vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. The Profectus proprietary vaccine design approach combines its plasmid (p) DNA and rVSV (recombinant Vesicular Stomatitis Virus) vectors platforms via a unique prime-boost strategy to enhance an immune response. Profectus has developed a broad pipeline of vaccine products to address Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), Herpes Simplex Virus (HSV) and Malaria. The company’s first clinical vaccine candidate for HIV is planned for clinical trials in Q4 of 2009, followed by a therapeutic HCV vaccine.

The Profectus portfolio has secured over $100M in non-dilutive funding of its programs from multiple sources including National Institutes of Health (NIH) and $19M in private equity financing, including Cross Atlantic Capital Partners (XACP). Profectus deploys these financial resources in support of its proprietary prime-boost vaccines for multiple indications. In addition, the Company is funding its early research small molecule program for potential partners. For more information, please visit: http://www.profectusbiosciences.com.